TNFRSF8 and Hodgkins lymphoma: AFM13 was studied in a phase I trial with patients with R/R CD30 + Hodgkin lymphoma (HL) with limited efficacy as monotherapy, likely due to the impaired function of autologous NK cells in these patients [115].